Art
J-GLOBAL ID：201402242843768607
Reference number：14A0572423
Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia
日本人の慢性骨髄性白血病患者におけるニロチニブの重度毒性とUGT1A1多型の間の関連
-
Publisher site
Copy service
{{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=14A0572423©=1") }}
-
Access JDreamⅢ for advanced search and analysis.
{{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=14A0572423&from=J-GLOBAL&jstjournalNo=L3966A") }}
Author (11)：
,
,
,
,
,
,
,
,
,
,
Material：
Volume：
19
Issue：
2
Page：
391-396
Publication year：
Apr. 2014
JST Material Number：
L3966A
ISSN：
1341-9625
Document type：
Article
Article type：
原著論文
Country of issue：
Germany, Federal Republic of (DEU)
Language：
ENGLISH (EN)
Thesaurus term：
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
Semi thesaurus term：
Thesaurus term/Semi thesaurus term
Keywords indexed to the article.
All keywords is available on JDreamIII(charged).
On J-GLOBAL, this item will be available after more than half a year after the record posted. In addtion, medical articles require to login to MyJ-GLOBAL.
,...
JST classification (3)：
JST classification
Category name(code) classified by JST.
Clinical application of antitumor(=antineoplastic)drugs
, Drug therapy(=pharmacotherapy)for tumors
, Blood cell tumors(=neoplasms)
Substance index (1)：
Substance index
Chemical Substance indexed to the Article.
Reference (18)：
-
Weisberg E, Manlew P, Mestan J et al (2006) AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 94:1765–1769
-
Saglio G, Kim D, Issaragrisil S et al (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251–2259
-
Hazarika M, Jiang X, Liu Q et al (2008) Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 14:5325–5331
-
Shami PJ, Deininger M (2012) Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 26:214–224
-
Kantarjian HM, Hochhaus A, Saglio G et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12:841–851
ｍore...
Terms in the title (7)：
Terms in the title
Keywords automatically extracted from the title.
,
,
,
,
,
,
Return to Previous Page
